Baopharma 宝济药业
Shanghai, China · baopharma.com
GMP
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Baopharma 宝济药业 develops and commercializes recombinant protein and antibody-based therapeutics. It operates in Shanghai, China, with additional affiliated offices in Suzhou, and focuses on drug development, manufacturing, and clinical advancement for biologics and recombinant enzymes.
Their website has a general contact form; we send your quote request through it.
What they offer
Recombinant human hyaluronidase solutions
Develops recombinant human hyaluronidase for subcutaneous drug delivery and combination use with small molecules and biologics.
Recombinant IgG cleaving enzyme development
Develops an IgG-degrading enzyme platform for rapidly lowering IgG in autoimmune disease, transplantation, and gene therapy settings.
Recombinant chymotrypsin development
Uses genetic engineering to develop chymotrypsin products as an alternative to traditional animal organ extraction methods.
Bispecific antibody formulation development
Develops KJ015, an anti-HER2 bispecific antibody formulated with Hysorptase for subcutaneous administration.
Biologics manufacturing
Manufactures therapeutic biological products using mammalian cell expression systems and bacterial/yeast expression systems.
Finished dosage form production
Produces injectable solutions, lyophilized powder injections, and pre-filled syringes.
Clinical development support
Advances products through clinical trial approvals and clinical trial programs in China and other regions.
What they work on
- Modalities
- Small molecule, Antibody, Bispecific, Recombinant protein
- Species and models
- mammalian cell expression systems, bacterial expression systems, yeast expression systems, Streptococcus pyogenes
- Scale and capacity
- approximately 63,000 square meters facility, 94 mu (approx. 15.5 acres) of land, 25,000-square-meter facility
- Therapeutic areas
- autoimmune diseases, rare diseases, organ transplantation, gene therapy, anti-GBM disease, kidney transplant, HER2-positive cancers, multiple myeloma
- Type
- CRDMO
- Sites
- Shanghai, China · Suzhou, China
- Quality
- cGMP-compliant (manufacturing facility) · Drug Manufacturing License Type A (production of therapeutic biological products (recombinant human hyaluronidase for injection)) · Drug Manufacturing License Type C (manufacture of recombinant human follicle-stimulating hormone-CTP fusion protein injection)
- Serves
- China, New Zealand
- Address
- 50 Luoxin Road from Shanghai Jingfeng Pharmaceutical Co., Ltd. in October 2021, enab
- Founded
- 2011
Similar labs. AbTherx, Aurigene Pharmaceutical Services, Bio X Cell, Biocytogen
Found in a contract services directory. Listing built from baopharma.com. Work here? Claim this listing.